Braxia Scientific Corp. (BRAXF)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 171.74 Thousand CAD | -4.06% |
| 2022 | -3.28 Million CAD | -13.51% |
| 2021 | -2.89 Million CAD | -32216.39% |
| 2020 | -8946.00 CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -133.44 Thousand CAD | 86.73% |
| 2024 Q3 | -324.72 Thousand CAD | 1706.61% |
| 2024 Q2 | 4538.00 CAD | 103.4% |
| 2023 Q1 | -439.84 Thousand CAD | 28.18% |
| 2023 FY | -3.41 Million CAD | -4.06% |
| 2023 Q4 | -1 Million CAD | -6.48% |
| 2023 Q3 | -944.21 Thousand CAD | 7.92% |
| 2023 Q2 | -1.02 Million CAD | -133.14% |
| 2022 FY | -3.28 Million CAD | -13.51% |
| 2022 Q2 | -1.05 Million CAD | -163.92% |
| 2022 Q1 | -400.25 Thousand CAD | -913.78% |
| 2022 Q3 | -1.21 Million CAD | -14.78% |
| 2022 Q4 | -612.45 Thousand CAD | 49.49% |
| 2021 FY | -2.89 Million CAD | -32216.39% |
| 2021 Q2 | 3603.00 CAD | -94.02% |
| 2021 Q1 | 60.23 Thousand CAD | 50097.5% |
| 2021 Q3 | 21.79 Thousand CAD | 505.0% |
| 2021 Q4 | -39.48 Thousand CAD | -281.12% |
| 2020 Q4 | 120.00 CAD | 0.0% |
| 2020 FY | -8946.00 CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 98.855% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -5436.525% |
| SQZ Biotechnologies Company | 9.79 Million USD | 98.246% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 98.533% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.856% |
| Mesoblast Limited | -35.16 Million USD | 100.488% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 602.908% |
| Genus plc | 178.7 Million USD | 99.904% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 58.128% |
| Marizyme, Inc. | 457.7 Thousand USD | 62.477% |
| ContraFect Corporation | -154 Thousand USD | 211.521% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1661.3% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 443.486% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -123.737% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -161.294% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 144.321% |
| MultiCell Technologies, Inc. | 49.32 USD | -348121.817% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.573% |
| EV Biologics, Inc. | 48.9 Thousand USD | -251.213% |
| Q BioMed Inc. | -8988.00 USD | 2010.803% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.392% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1213.479% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.922% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -145.347% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 238.223% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -175.999% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 3568.154% |
| Arch Therapeutics, Inc. | -2439.00 USD | 7141.533% |
| IMV Inc. | -962.29 Thousand USD | 117.847% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -22.237% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 276.12% |
| GB Sciences, Inc. | -624.00 USD | 27622.917% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 299.636% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.998% |
| Halberd Corporation | -208.00 USD | 82668.75% |
| Enzolytics Inc. | 30.7 Thousand USD | -459.278% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 87.345% |
| SYBLEU INC | 11.69 Thousand USD | -1368.391% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 64.401% |
| argenx SE | 1.1 Billion USD | 99.985% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.666% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 72.182% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.958% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2039.284% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.613% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 115.044% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 82.617% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 98.213% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 304.824% |
| BioStem Technologies, Inc. | 15.42 Million USD | 98.887% |
| ONE Bio Corp. | 20.12 Million USD | 99.147% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1551.145% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 455.878% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 2.728% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 2.728% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 133.38% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 127.255% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 692.217% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 61.839% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 153.752% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 96.273% |
| Bioxytran, Inc. | -8285.00 USD | 2172.939% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 146.044% |
| Neutra Corp. | 14.33 Thousand USD | -1098.068% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 309.443% |
| PureTech Health plc | -1.6 Million USD | 110.714% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 117.153% |
| IXICO plc | 3.27 Million USD | 94.748% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 124.747% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 109.589% |
| CSL Limited | 7.7 Billion USD | 99.998% |
| Cellectis S.A. | 18 Thousand USD | -854.128% |